UK: Inside IP: No Interim Injunction Following Obviousness Ruling On Tadalafil Dosage Patent

Last Updated: 1 December 2017
Article by David Rose and Daniel Levy

In a rare intervention in relation to inventive step, the Court of Appeal has overturned a High Court decision of Mr Justice Birss in relation to ICOS/Lilly's tadalafil 5mg dosage regimen patent. Tadalafil is the generic name of the drug sold under the brand 'Cialis' for the treatment of male erectile dysfunction (ED).

The inventive concept of the patent was stated to be a smaller 5mg dosage of tadalafil, which remained effective but was combined with minimal side effects.  However, the appeal court found that there was no invention in a dose that was discovered by virtue of the dose ranging studies carried out as part of routine Phase IIb clinical studies.  The patent (EP (UK) 1,173,181) was therefore invalid, and with the Supplementary Protection Certificate for tadalafil also expiring in November, the way became clear for Actavis, Teva and Mylan to launch generic products to compete with Cialis.

Having applied for permission to appeal to the Supreme Court, Lilly made an urgent application in the Patents Court for an interim injunction to stop generic products entering the market, pending any possible appeal.  An appeal to the Supreme Court can take some time to resolve (around one to two years from filing the petition to judgment) - if the interim injunction had been granted, this would have meant generic manufacturers would potentially have to factor in the likely timing of an appeal to the Supreme Court when taking steps to clear the way before launch. 

In the event, such policy arguments did not impact on the Patents Court's decision refusing to grant an interim injunction. The judge, Mr Justice Henry Carr, concluded that Lilly did not have a realistic prospect of success in a further appeal, as the Court of Appeal had applied the facts, as found by the High Court, to existing and settled principles of law. Further, he would also have been against Lilly on the question of unquantifiable loss (not least as, following the accepted downward price spiral, the patent would expire not long after a period of restored monopoly). In contrast, he accepted that the generic companies would all lose their 'first mover' advantage, outweighing any unquantifiable losses to Lilly. 

Whether or not a distinct dosage regime of a known compound can be inventive is an important policy question underlying this litigation.  Whilst the Court of Appeal's decision does not rule this out, it did not consider there to be an invention on the facts of this case. The claimed invention lay "at the end of the familiar path through the routine pre-clinical and clinical trials process" and the skilled team would embark on that process with a reasonable expectation of success, and would carry out Phase IIb dose ranging studies, including to find out the dose response relationship.  It was very likely that, in doing so, they would test a 5mg daily dose and would find it safe and efficacious. 

Trial decision: not obvious

'Daugan', the prior art over which the patent was alleged by Actavis to be obvious, disclosed the use of PDE5 inhibitors to treat ED, and specifically disclosed tadalafil (giving an example of a 50mg dose). However, it did not disclose (specifically) a 5mg daily dose of tadalafil or that such a dose would be an effective treatment for ED. 

Mr Justice Birss, in the High Court, found it would have been entirely obvious for a skilled team, on the basis of Daugan, to take tadalafil into a routine pre-clinical and clinical trial programme, and would have investigated on demand and chronic daily dosing.  The skilled team would have embarked on a Phase 11a study and then routine Phase IIb dose ranging studies, based on 25, 50 and 100mg initially.  However, the question was the extent to which the skilled team would be motivated, as part of the Phase IIb clinical trial, to: (a) investigate whether lower dosages would also display a dose response relationship; and (b) discover the minimum effective dose.  Mr Justice Birss's view was that 5mg is a significantly lower dose than 50mg and, even if a test was carried out on a 5mg/day dose, it would not be tested with a reasonable expectation of success and would be the culmination of a series of value judgments. 

Court of Appeal decision: obvious

Lord Justice Kitchin acknowledged that it is very easy with hindsight to say something is obvious, but noted that the number of open research avenues was also important.  In this case, there were a number of choices including whether to pursue on demand or daily dosing.  After Phase 1, Mr Justice Birss found that both avenues would be pursued.

The Court of Appeal found, however, that Mr Justice Birss placed too much emphasis on 5mg being substantially lower than 50mg, meaning 5mg would therefore not be used in the first (or even, in the case of on demand dosing, second) round of a routine dose ranging study, even if it was very likely that it would be subsequently investigated.  The very purpose of Phase IIb of a clinical study is to understand the parameters of a given dose response relationship – Lord Justice Floyd stating that "far from being a value judgment, investigating lower doses was something the skilled team would do without further thought". It would not matter that it was not previously known that 5mg was safe and efficacious; instead this stage of the study would continue until complete. 

The skilled team's reasonable expectation of success would relate only to the expectation of success in understanding the dose response relationship in question (the objective of the Phase IIb), rather than the effectiveness of a specific dose.  Furthermore, it is irrelevant from an obviousness perspective that the result is surprising, since a surprising result does not make routine enquiries inventive.

Comment

Lilly is currently seeking permission to appeal to the Supreme Court, but the Patents Court's decision to refuse an interim injunction and, in doing so, its rejection of its attacks on the Court of Appeal's decision will be a setback. Alongside Lord Justice Kitchin, Lord Justices Floyd and Lewison also took the opportunity to express their views in relation to the 'obvious to try' line of cases. In particular, Lord Justice Lewison noted that the Court of Appeal had been "at pains" in previous decisions "to warn against the over-elaboration of the 'obvious to try' line of cases", concluding that in a case involving routine pre-clinical and clinical trials, what would be undertaken as part of that routine, was unlikely to be inventive.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions